Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 2523 • ACR Convergence 2025
Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
Yusuke Ushio¹, Satoshi Omura², Daiki Nakagomi³, Yoshiyuki Abe⁴, Makoto Wada⁵, Naoho Takizawa⁶, Atsushi Nomura⁷, Yuji Kukida⁸, Naoya Kondo⁹, Hirosuke Takagi¹⁰, Koji Endo¹¹, Shintaro Hirata¹², Naoto Azuma¹³, Tohru Takeuchi¹⁴, Shoichi Fukui¹⁵, Kazuro Kamada¹⁶, Ryo Yanai¹⁷, Yusuke Matsuo¹⁸, Yasuhiro Shimojima¹⁹, Ryo Nishioka²⁰, Ryota Okazaki²¹, Tomoaki Takata²², Mayuko Moriyama²³, Ayuko Takatani²⁴, Yoshia Miyawaki²⁵, Tsuyoshi Shirai²⁶, Takafumi Ito²⁷, Isao Matsumoto²⁸, Toshihiko Takada²⁹, Toshiko Ito-Ihara³⁰, Takashi Kida³¹, Nobuyuki Yajima¹⁷, Takashi Kawaguchi³², Yutaka Kawahito³¹ and Hiroaki Dobashi³³, ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita District, Kagawa, Japan, ²Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, ⁴⁶⁵, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan, ³Department of Rheumatology, University of Yamanashi Hospital, Chuo-shi, Yamanashi, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University, Bunkyo-Ku, Tokyo, Japan, ⁵Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto-shi, Kyoto, Japan, ⁶Department of Rheumatology, Chubu Rosai Hospital, Nagoya city, Aichi, Japan, ⁷Immuno-Rheumatology Center, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁸Department of Rheumatology, Japanese Red Cross Society Kyoto Daini Hospital, Kamigyou, Kyoto, Japan, ⁹Department of Nephrology, Kyoto Katsura Hospital, Nishikyo-ku, Kyoto, Japan, ¹⁰Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Kagoshima, Japan, ¹¹Department of General internal medicine, Tottori Red Cross Hospital, Tottori-city, Tottori, Japan, ¹²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ¹³Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, ¹-¹ Mukogawa-cho, Nishinomiya-shi, Hyogo, Japan, ¹⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan, ¹⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ¹⁷Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Kyosai Hospital, Meguro-ku, Tokyo, Japan, ¹⁹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan, ²⁰Department of Nephrology and Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan, ²¹Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan, ²²Division of Gastroenterology and Nephrology, Tottori University, Yonago, Tottori, Japan, ²³Department of Rheumatology, Shimane University Faculty of Medicine, Izumo-shi, Shimane, Japan, ²⁴Rheumatic Disease Center, Sasebo Chuo Hospital, Sasebo-shi, Nagasaki, Japan, ²⁵Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ²⁶Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, ²⁷Division of Nephrology, Department of Internal Medicine, Teikyo University Chiba Medical Center, Ichiharashi, Chiba, Japan, ²⁸Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan, ²⁹Department of General Medicine, Shirakawa Satellite for Teaching And Research (STAR) Fukushima Medical University, Shirakawa, Fukushima, Japan, ³⁰The Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan, ³¹Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan, ³²Department of Clinical Assessment, Tokyo University of Pharmacy and Life Sciences, Hachioji-city, Tokyo, Japan, ³³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Glucocorticoids (GCs) are a cornerstone of remission induction therapy in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), but long-term GC use is associated…
Abstract Number: 2505 • ACR Convergence 2025
Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
BEATRIZ MARIA FRANCO HONDERMANN, LOYOLA UNIVERSITY MEDICAL CENTER, OAK PARK
Background/Purpose: Avacopan is a novel C5a receptor inhibitor recently approved for treatment of ANCA-associated vasculitis as an alternative to glucocorticoids, It has demonstrated superior efficacy…
Abstract Number: 1606 • ACR Convergence 2025
One Year Real-World Effectiveness with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Large Healthcare System
Naomi Patel¹, Andrew King², Madison Negron³, Zachary Williams⁴, Ana Fernandes¹, Nora Shepherd², Colebrooke Johnson¹, Guy Katz¹, Belen Arevalo Molina¹, Elizabeth Ibiloye⁵, Sam Oh⁶, Zachary Wallace⁷ and Sebastian H Unizony⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Harvard Extension School, Medford, MA, ⁴Massachusetts General Hospital, Nancy, KY, ⁵Amgen Inc, Thousand Oaks, CA, ⁶Amgen Inc, South San Francisco, CA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Avacopan has been approved for adjunctive use in adults with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the US. Here…
Abstract Number: 0900 • ACR Convergence 2025
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
Charlotta Preger¹, Maria Aspenberg¹, Metta Berenpas¹, Armita Dwivedi², Juliana Bordignon Draibe³, Peter Nilsson¹, Mark A. Little² and Elisa Pin¹, ¹Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ²Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ³Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…
Abstract Number: 0727 • ACR Convergence 2025
Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
Sehreen Mumtaz¹, Kindalem Fentie², Joseph Parker², Emily Craver¹, Vikas Majithia³ and Andy Abril⁴, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic Hospital, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville
Background/Purpose: Hearing loss in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is one of the commonly reported manifestations of organ damage in AAV with predominantly…
Abstract Number: 2522 • ACR Convergence 2025
Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study
Yuko Shirota¹, Misa Oguma², MIki Kubota², Kei Soeda², Yumi Tajima², Ryo Kuwata³, Yumiko Oka², Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³AIDS Clinical Center of the National Center for Global Health and Medicine, Shinjyuku, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilia and granuloma formation, affecting multiple organs. The Five-Factor Score (Medicine, 2011) identifies key…
Abstract Number: 2504 • ACR Convergence 2025
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Anuya Natu¹, Isadora Small², Shilpa Arora³ and Augustine Manadan⁴, ¹John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ²The Latin School of Chicago, Chicago, IL, ³Cook County Hospital, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 0722 • ACR Convergence 2025
Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids
Mats Junek¹, Quazi Ibrahim², Peter Merkel³, Eswari Vilayur⁴, Ron Wald⁵, Todd Fairhead⁶, David Massicotte-Azarniouch⁶, Louis Girard⁷, Christian Pagnoux⁸, Nader Khalidi², David Jayne⁹ and Michael Walsh², ¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³University of Pennsylvania, Philadelphia, PA, ⁴John Hunter Hospital, Newcastle, New South Wales, Australia, ⁵St Michael's Hospital, Toronto, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹University of Cambridge, Cambridge, United Kingdom
Background/Purpose: People with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) vary in their risk of a relapse of disease. Estimating an individual’s risk may inform…
Abstract Number: 0726 • ACR Convergence 2025
Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
Sebastian E Sattui¹, Elizabeth Ibiloye², Niranjan Kathe³, Sam Oh⁴, Virginia Noxon-Wood⁵, Iman Mohammadi⁵, Laura Moore-Schiltz⁵ and Tingting Li⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, San Diego, CA, ⁴Amgen Inc, South San Francisco, CA, ⁵Inovalon, Bowie, MD, ⁶Washington University School of Medicine, St. Louis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most common types of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Treatment-related toxicities, particularly from glucocorticoid…
Abstract Number: 2521 • ACR Convergence 2025
DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: The DANGER score can predict mortality in patients with ANCA-associated vasculitis (AAV) with glomerulonephritis (GN). However, this score has not been widely validated and,…
Abstract Number: 2452 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Sanbin Wang¹, Heng Mei², Dongmei Zhou³, Wei Xie², Songlou Yin³, Chunmei Liu³, Hanwei Wang⁴, Huan Zhou⁵, Yue Xie⁶, Lu Han⁷, Jiangtao Ren⁸, Yali Zhou⁸, Wengang Ge⁷ and Jan Davidson-Moncada⁸, ¹⁹²⁰th Hospital of Joint Logistic Support Force, Kunming, China (People's Republic), ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ³The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China (People's Republic), ⁴The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), ⁶Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ⁷Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁸Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…
Abstract Number: 1603 • ACR Convergence 2025
SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Julia Foos¹, Naveed Shah² and Nezam Altorok³, ¹Unversity of Toledo College of Medicine and Life Sciences, Toledo, ²University of Toledo College of Medicine and Life Sciences, Toledo, ³The University of Toledo, Toledo, OH
Background/Purpose: ANCA-associated vasculitis encompasses three main conditions: Granulomatosis with Polyangiitis (GPA, previously called Wegener’s granulomatosis), Eosinophilic Granulomatosis with Polyangiitis (EGPA, previously called Churg-Strauss), and microscopic…
Abstract Number: 0721 • ACR Convergence 2025
Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Mats Junek¹, Sara Choi², Stephanie Garner³, Saara Rawn⁴, David Cuthbertson⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Ulrich Specks¹³, Kenneth Warrington¹³, Gerard Cox¹, Nader Khalidi¹⁴ and Peter Merkel⁸, ¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ²Queen's University, Kingston, ON, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴NOSM School of Medicine, Sudbury, ON, Canada, ⁵University of South Florida, Tampa, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴McMaster University, Hamilton, ON, Canada
Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
Abstract Number: 0724 • ACR Convergence 2025
Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Milad Heydari-Kamjani¹, Elleson Harper² and Haseeb Chaudhary³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University, Westlake, OH
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune vasculitis. Avacopan, a novel oral C5a receptor inhibitor, has emerged as an adjunct therapy…

1
2
3
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].